Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 655.56% | 36.77% | 143.58% | -8.30% | 104.83% |
| Total Depreciation and Amortization | -8.96% | -12.16% | -5.71% | -13.37% | -19.36% |
| Total Amortization of Deferred Charges | -66.67% | -61.40% | -217.54% | -43.82% | 590.00% |
| Total Other Non-Cash Items | 232.58% | 142.86% | -120.72% | -63.23% | -429.63% |
| Change in Net Operating Assets | -21.74% | -299.30% | -0.30% | 244.19% | -170.08% |
| Cash from Operations | 82.11% | -348.91% | 156.17% | 141.52% | 65.98% |
| Capital Expenditure | 66.67% | 85.09% | 53.97% | 63.20% | 28.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 650.93% | 350.88% | 692.59% | -101.79% | 28.48% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -862.70% | 87.81% | -5.95% |
| Issuance of Common Stock | -- | 14.29% | -- | -92.63% | -- |
| Repurchase of Common Stock | -25.00% | -200.00% | -200.00% | 0.00% | 80.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.98% | -89.36% | -319.30% | 89.55% | 487.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.34% | -312.55% | 10,775.00% | 97.66% | 84.60% |